June 10, 2019
NRG Oncology Broadcast archives are accessible from our website at any time. Please bookmark  this link  for your convenience.

NCI ComboMatch Study
Submission Deadline Extension

NRG Oncology is soliciting concepts for the NCI ComboMatch study. This trial will focus on rational combinations of agents supported by preclinical in vivo evidence. Read more

 
 

Only 15 days left to have your registration fee waived!

We hope you can join us for the NRG Oncology Semiannual Meeting, July 18-20, 2019, at the Philadelphia Marriott Downtown in Philadelphia, PA. Pre-Registration for this meeting is complimentary for all NRG members who pre-register by the deadline of June 25, 2019. We kindly ask that everyone please pre-register for this meeting before the deadline. Onsite registration will incur a $100 fee.

 

Registration and meeting information is available on the NRG Oncology website.

 

Meeting Highlights

  • Patient Reported Outcomes: Upping the game for PRO methods and design in clinical trials - 

    NRG Oncology will be holding a workshop at the NRG Semiannual Meeting related to improving statistical methods to meet study goals, analyzing longitudinal PRO data as well as a panel discussion with NCORP PIs. This session will be held on Thursday, July 18, 2019 from 1-5pm and will be open to all attendees. The agenda can be found here.

  • Summer Symposium: Thursday, July 18 -  8am-3pm Read more
  • Scientific Session: Friday, July 19 -  8-10am
  • Health Disparities Workshop Special Session: Sexual and Gender Minority Related Activities at the NIH - Friday, July 19 - 10-11:30am Read more
  • Social Media Workshop: Friday, July 19 - 11:30am-12:30pm  Read more

SAVE THE DATE: Information Session for NRG-BN006

NRG Oncology will be holding an information session for NRG-BN006: A Phase II/III Randomized, Open-Label Study of Toca 511, A Retroviral Replicating Vector, Combined with Toca FC with Temozolomide and Radiation Followed by Adjuvant Temozolomide and Toca FC Compared to Temozolomide and Radiation Followed by Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma on Friday, July 19, 2019 from 10:30-11am ET. The information session will be held at the NRG Oncology Semiannual Meeting in Philadelphia and is open to all attendees. More information on the information session agenda and room location will be released soon. Please contact Erin Moye at moyee@nrgoncology.org for any questions at this time.

 

SAVE THE DATE: Kick-Off Session for NRG-GU007

NRG Oncology will be holding a kick-off session for NRG-GU007: Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I) on Friday, July 19, 2019 from 11am-12pm ET. The information session will be held at the NRG Oncology Semiannual Meeting in Philadelphia and is open to all attendees. More information on the kick-off session agenda and room location will be released soon. Please contact Erin Moye at moyee@nrgoncology.org for any questions.

SAVE THE DATE: Kick-Off Session for NRG-LU003

NRG Oncology will be holding a kick-off session at the NRG Oncology Semiannual Meeting for NRG-LU003 “A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol.” The session will be held on Saturday, July 20, 2019 from 10:30-11:30am ET and will be open to all attendees. More information on the session and agenda are posted here. Please contact Erica Field at fielde@nrgoncology.org for any questions.

 

SAVE THE DATE: Kick-Off Session for NRG-LU005

NRG Oncology will be holding an kick-off session for NRG-LU005: Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab on Friday, July 19, 2019 from 3-4pm ET. The kick-off session will be held at the NRG Oncology Semiannual Meeting in Philadelphia and is open to all attendees. More information on the kick-off session agenda and room location will be released soon.  Please contact Erin Moye at moyee@nrgoncology.org for any questions.

 

Social Media Workshop 1-on-1's at #NRG19

Are you ready to get started on Twitter?  Let our social media experts show you how simple it is to set up a new account or make your existing account more engaging. At #NRG19, we have scheduled two Social Media 1-on-1 Workshops where our Twitter experts will be on hand to show you the how-to's of Twitter. If you are interested in learning more about tweeting, retweeting, hashtags, following, and more, stop by during one of the following sessions and bring your smartphone &/or laptop. No previous social media experience required! Friday, July 19, 12:30-1pm and Saturday, July 20, 10-11am.


ACTIVATION AND TEMPORARY CLOSURE

GENITOURINARY

NRG-GU007: Activation and Temporary Closure Date: June 3, 2019. The protocol will reopen to accrual pending processing of amendment 1 (posted on CTSU).

 

OTHER PROTOCOL NOTICES

1. GASTROINTESTINAL

NRG-GI004: Announcement regarding reimbursement for baseline/screening ECG (Announcement posted on  CTSU).


2. GYNECOLOGIC

 NRG-GY009: Block Submission Reminder memo (posted on  CTSU)

 

Form TR for Biospecimens Shipped to NRG Biospecimen Bank-Columbus Read more

 

Biospecimen Bank-Columbus & SDMC Undergoing Refurbishment Read more

 

3. VTOC TRAINING

The VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on RTOG 0924, RTOG 0920, NRG-HN001, NRG-HN002, NRG-CC003, and NRG-CC004. Space is limited so register now and reserve your seat.  The next webinar training is scheduled for Wednesday, June 12.

 

DRUG SAFETY UPDATES

Safety updates have been issued for the following studies:

DRUG NAME

PROTOCOL

WEBSITE FOR SAFETY REPORTS

Ipilimumab

NRG-BN002

NRG-GY003

NRG

NRG

Nivolumab

NRG-BN002

NRG-GY003

NRG

NRG

Olaparib

NSABP B-55

CTSU

Pembrolizumab

NRG-GI002
NRG-GY016
NRG-HN003

CTSU

CTSU
NRG

Trametinib

GOG-0281

CTSU

 

NCI ComboMatch Study – Submission Deadline Extension

NRG Oncology is soliciting concepts for the NCI ComboMatch study. This trial will focus on rational combinations of agents supported by preclinical in vivo evidence. Submission Due Date: June 25, 2019.  Please note that IO combinations are NOT permitted for the ComboMatch study.  Read more

 

Dr. Markham elected ASCO Cancer Communications Committee Chair
Merry-Jennifer Markham, MD, has been elected Chair of the American Society of Clinical Oncology Cancer Communications Committee. Dr. Markham is a current member of the NRG Oncology Communications Committee and the NRG Oncology Ovarian Cancer Subcommittee. Congratulations to Dr. Markham!

CRA and CTN Mentorship Program

Are you a new CRA or CTN in NRG Oncology? Do you need general information to help you get started in NRG Oncology? Well, we have the solution for you! The NRG Oncology Mentorship Working Group would like to remind you of a valuable resource. The “Introductory Materials” for CRAs and CTNs is available on the NRG Oncology website for your use. This online resource was designed to make the introduction to NRG Oncology as smooth as possible by providing information regarding specific processes and contacts to be used when conducting NRG Oncology clinical trials. The information is intended to assist new members in understanding how NRG Oncology trials operate and who to contact when there are questions or difficulties. Please see materials on the NRG Oncology website.

NRG Oncology is pleased to report the scientific articles and abstracts that have appeared or have been presented during the previous week. This publications report includes links, when available, to the article, PubMed abstract, or association abstract.

JOURNAL ARTICLES

Nie K, Al-Hallaq H, Li XA, Benedict SH, Sohn JW, Moran JM, Fan Y, Huang M, Knopp MV, Michalski JM, Monroe J, Obcemea C, Tsien CI, Solberg T, Wu J, Xia P, Xiao Y, El Naqa I. NCTN Assessment on Current Applications of Radiomics in Oncology. Int J Radiat Oncol Biol Phys. 2019 Jun 1;104(2):302-315. doi: 10.1016/j.ijrobp.2019.01.087. Epub 2019 Jan 31. Review. PubMed PMID: 30711529; PubMed Central PMCID: PMC6499656.   Read more

Thor M, Deasy JO, Paulus R, Robert Lee W, Amin MB, Bruner DW, Low DA, Shah AB, Malone SC, Michalski JM, Dayes IS, Seaward SA, Gore EM, Albert M, Pisansky TM, Faria SL, Chen Y, Koontz BF, Swanson GP, Pugh SL, Sandler HM. Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415. Radiother Oncol. 2019 Jun;135:19-24. doi: 10.1016/j.radonc.2019.02.014. Epub 2019 Mar 5. PubMed PMID: 31015166.  Read more

ACCEPTED MEETING ABSTRACT

Higgins K, Hu C, Ross HJ, Jabbour S, Kozono D, Owonikoko TK, Movsas B, Xiao C, Solberg TD, Williams T, Welsh J, Simko JP, Wang X, Stinchcombe TE, Bradley JD. NRG Oncology/Alliance LU005: A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab in Limited Stage Small Cell Lung Cancer. IASLC (International Association for the Study of Lung Cancer). Sep 7, 2019.  Trial in Progress poster.

PUBLICATIONS REMINDERS

Please note the following upcoming meeting and abstract submission deadline dates

Upcoming Meetings

American Brachytherapy Society (ABS); Jun 13-15, 2019; Miami, FL

 

Western Association of Gynecologic Oncologists (WAGO); Jun 12-15, 2019; Huntington Beach, CA

 

Upcoming Abstract Submission Deadlines

 

European Society for Medical Oncology (ESMO); Sep 27-Oct 1, 2019; Barcelona, Spain; LBA Aug 21, 2019 9:00 pm CEST

 

San Antonio Breast Cancer Symposium (SABCS); Dec 10-14, 2019; San Antonio, TX; due to publications committee Jun 24, 2019; meeting submission deadline Jul 8, 2019

NRG Oncology is proud to be an active participant of #CancerMoonShot.
This message was sent from NRG-Broadcasts@NRGOncology.org to NRG-Broadcasts@NRGOncology.org
Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Update Profile/Email Address | Forward Email | Report Abuse